Annals of oncology : official journal of the European Society for Medical Oncology

publication venue for

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. 2018
Selective RET kinase inhibition for patients with RET-altered cancers. 2018
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. 2017
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). 2017
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). 2016
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. 2015
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. 2015
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. 2014
Second cancers complicating Hodgkin's disease. 1996
Deciphering radiological stable disease to immune checkpoint inhibitors.. 33. 2022
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.. 33. 2022
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.. 32. 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.. 32. 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.. 32. 2021
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study^☆.. 31. 2020
COVID-19 in patients with lung cancer.. 31. 2020
Characterization of on-target adverse events caused by TRK inhibitor therapy.. 31. 2020
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.. 31. 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.. 31. 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.. 31. 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.. 31. 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.. 30. 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).. 30. 2019
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.. 30. 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.. 30. 2019
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.. 30. 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.. 30. 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.. 30. 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.. 30. 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.. 30. 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.. 30. 2019
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. 30. 2019
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.. 30. 2019
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.. 30. 2019
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.. 30. 2019
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.. 30. 2019
Novel therapies in urothelial carcinoma: a biomarker-driven approach.. 29. 2018
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.. 29. 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.. 29. 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.. 29. 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.. 29. 2018
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.. 29. 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.. 29. 2018
Different menopausal hormone regimens and risk of breast cancer.. 29. 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).. 29. 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. 29. 2018
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.. 29. 2018
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.. 29. 2018
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.. 29. 2018
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.. 29. 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.. 29. 2018
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.. 29. 2018
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).. 29. 2018
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.. 29. 2018
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.. 29. 2018
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).. 28. 2017
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.. 28. 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.. 28. 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).. 28. 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.. 28. 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.. 28. 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. 28. 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.. 28. 2017
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.. 28. 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.. 28. 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.. 28. 2017
Oncologist use and perception of large panel next-generation tumor sequencing.. 28. 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.. 28. 2017
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.. 28. 2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. 28. 2017
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.. 28. 2017
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).. 28. 2017
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.. 28. 2017
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.. 28. 2017
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.. 28. 2017
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.. 28. 2017
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.. 27. 2016
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.. 27. 2016
Consensus on precision medicine for metastatic cancers: a report from the MAP conference.. 27. 2016
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. 30. 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.. 27. 2016
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.. 27. 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.. 27. 2016
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.. 27. 2016
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.. 27. 2016
Neoadjuvant chemotherapy in ovarian cancer revisited.. 27 Suppl 1. 2016
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.. 27. 2016
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.. 27. 2016
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.. 27. 2015
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).. 27. 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.. 27. 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.. 27. 2015
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.. 27. 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.. 26. 2015
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.. 26. 2015
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.. 26. 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.. 26. 2015
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.. 26. 2015
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.. 26. 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.. 25. 2014
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.. 25. 2014
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.. 25. 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.. 25. 2014
Survival of women with inflammatory breast cancer: a large population-based study.. 25. 2014
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).. 25. 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.. 25. 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.. 25. 2014
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.. 25. 2014
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.. 25. 2014
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.. 25. 2013
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.. 25. 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).. 24. 2013
Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4).. 24. 2013
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.. 24. 2013
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.. 24. 2013
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial.. 24. 2013
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients.. 24. 2013
Efficacy of multimodal exercise-based rehabilitation on physical activity, cardiorespiratory fitness, and patient-reported outcomes in cancer survivors: a randomized, controlled trial.. 24. 2013
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.. 24. 2013
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.. 24. 2013
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.. 24. 2013
Attitudes of patients with metastatic breast cancer toward research biopsies.. 24. 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.. 24. 2013
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.. 24. 2013
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.. 24. 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.. 24. 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.. 24. 2012
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.. 24. 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.. 24. 2012
Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).. 23. 2012
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.. 23. 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.. 23. 2012
Palliative oncology: identity, progress, and the path ahead.. 23 Suppl 3. 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.. 23. 2012
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.. 23. 2012
Extending the clinical research network approach to all of healthcare.. 22 Suppl 7. 2011
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.. 23. 2011
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.. 23. 2011
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.. 23. 2011
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.. 23. 2011
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.. 23. 2011
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.. 23. 2011
Histology and outcomes of newly detected lung lesions in melanoma patients.. 23. 2011
Lung cancer physicians' referral practices for palliative care consultation.. 23. 2011
Identifying factors that impact survival among women with inflammatory breast cancer.. 23. 2011
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.. 23. 2011
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.. 23. 2011
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.. 23. 2011
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.. 23. 2011
Toxicity burden score: a novel approach to summarize multiple toxic effects.. 23. 2011
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.. 22. 2011
Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.. 23. 2011
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.. 22. 2011
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?. 22. 2011
GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.. 22. 2011
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.. 22. 2011
Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4).. 22. 2011
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.. 22. 2011
Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts.. 22. 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.. 22. 2010
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.. 22. 2010
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.. 22. 2010
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.. 22. 2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.. 22. 2010
Phase I trial of SU14813 in patients with advanced solid malignancies.. 22. 2010
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.. 22. 2010
Incidence of and survival following brain metastases among women with inflammatory breast cancer.. 21. 2010
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors.. 21. 2010
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.. 21. 2010
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.. 21. 2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.. 21. 2010
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.. 21. 2010
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.. 21. 2009
Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.. 21. 2009
Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.. 21. 2009
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.. 21. 2009
Circulating tumor cells in metastatic inflammatory breast cancer.. 20. 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.. 20. 2009
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.. 20. 2009
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.. 20. 2009
Expanding the boundaries of clinical practice: building on experience with targeted therapies.. 20 Suppl 1. 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.. 20. 2009
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.. 20. 2009
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.. 20. 2009
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.. 20. 2009
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.. 20. 2009
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.. 20. 2009
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).. 20. 2009
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.. 20. 2008
Detection of circulating tumor cells in patients with urothelial cancer.. 20. 2008
Newer opportunities in systemic therapy of lung cancer.. 19 Suppl 7. 2008
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.. 19 Suppl 7. 2008
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.. 20. 2008
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.. 19. 2008
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.. 19. 2008
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.. 19. 2008
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.. 19. 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.. 19. 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.. 19. 2008
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age.. 19. 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.. 19. 2008
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.. 19. 2008
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.. 19. 2007
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.. 18. 2007
Systemic chemotherapy does not increase the risk of gastrointestinal perforation.. 18. 2007
Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience.. 19. 2007
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.. 19. 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.. 18. 2007
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.. 18. 2007
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.. 18. 2007
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.. 18. 2007
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.. 18. 2007
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.. 18. 2007
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.. 18. 2007
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.. 18. 2006
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.. 17. 2006
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.. 17. 2006
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.. 17. 2006
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.. 17. 2006
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.. 17. 2006
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.. 17. 2006
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm.. 17. 2006
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.. 17. 2006
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.. 17. 2006
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.. 17. 2006
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.. 17. 2005
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.. 16. 2005
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.. 16. 2005
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.. 16. 2005
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases.. 16. 2005
CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients.. 15. 2004
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.. 15. 2004
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer.. 15. 2004
Recommendations for a Global Core Curriculum in Medical Oncology.. 15. 2004
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.. 15. 2004
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.. 15. 2004
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.. 15. 2004
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma.. 15. 2004
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.. 15. 2004
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.. 15. 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.. 15. 2004
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.. 15. 2004
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.. 15. 2004
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.. 15. 2004
Twenty-five years of treating advanced NSCLC: what have we achieved?. 15 Suppl 4. 2004
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.. 14. 2003
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity.. 14. 2003
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).. 14. 2003
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.. 13. 2002
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.. 13. 2002
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.. 13. 2002
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.. 13. 2002
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.. 13. 2002
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.. 13. 2002
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.. 12. 2001
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.. 12. 2001
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients.. 12. 2001
A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.. 12. 2001
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.. 12. 2001
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients.. 11. 2000
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.. 11. 2000
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.. 11. 2000
The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why.. 11. 2000
Caelyx in malignant mesothelioma: a phase II EORTC study.. 11. 2000
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.. 11. 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.. 11. 2000
A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma.. 11. 2000
Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure.. 11 Suppl 1. 2000
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy.. 10. 1999
Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.. 10. 1999
Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.. 10. 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.. 10. 1999
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.. 10. 1999
Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996.. 10. 1999
Role of endoscopic stenting in the duodenum.. 10 Suppl 4. 1999
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.. 9. 1998
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.. 9. 1998
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.. 9. 1998
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.. 9. 1998
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.. 8. 1997
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.. 8. 1997
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.. 8. 1997
Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).. 8. 1997
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study.. 8. 1997
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy.. 8. 1997
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach.. 8. 1997
Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.. 8 Suppl 2. 1997
Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma.. 8 Suppl 2. 1997
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma.. 7. 1996
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.. 7. 1996
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.. 7. 1996
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.. 7. 1996
A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial.. 7. 1996
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.. 7. 1996
Gene therapy--the challenge for the future.. 7 Suppl 2. 1996
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients.. 6. 1995
Prognostic relevance of P-glycoprotein expression in breast cancer.. 6. 1995
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer.. 6. 1995
Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer.. 6. 1995
A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome.. 6. 1995
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.. 5. 1994
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.. 5 Suppl 6. 1994
A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG).. 4. 1993
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.. 4. 1993
Carboplatin and 5-fluorouracil in poor performance status patients with advanced urothelial cancer.. 4. 1993
Recombinant tumor necrosis factor for superficial bladder tumors.. 3. 1992
Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.. 2 Suppl 2. 1991
Factors affecting the outcome of autologous bone marrow transplantation.. 2 Suppl 1. 1991
Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231].. 32. 2021
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.. 27. 2016
'Genotype/immunotype' correlations in resected NSCLC. 2017
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. 2017
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy. 2015
Letter to the editor concerning 'Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis'. 2015
Atypical femur fractures associated with use of bisphosphonates and denosumab. 2015
T-DM1-related telangiectasias: a potential role in secondary bleeding events. 2014
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. 2013
Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200. 2013
Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies? 2013
Specific PPAR gamma agonists may have different effects on cancer incidence. 2013
Capecitabine dosing is not yet optimized for breast cancer. 2010
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis. 2009
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. 2007
Irinotecan chemotherapy associated with transient dysarthria and aphasia. 2004
Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast. 1996
Carboplatin and etoposide in metastatic breast cancer. 1995
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). 2017
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 2015
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. 2015
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. 2015
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. 2013
New insights into pancreatic cancer biology. 2012
Novel hormonal therapy for castration-resistant prostate cancer. 2012
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. 2010
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. 2010
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. 2007
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. 2006
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. 2005
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. 2005
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer.. 32. 2020
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.. 31. 2020
Panel-based estimates of tumor mutational burden: characterizing unknown unknowns.. 30. 2019
Developing androgen receptor targeting for salivary gland cancers.. 29. 2018
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.. 28. 2017
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?. 28. 2017
Cabozantinib: targeted therapy back to the future?. 28. 2017
Atypical autoimmune adverse effects with checkpoint blockade therapies.. 28. 2017
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity.. 28. 2017
Prioritizing precision medicine for prostate cancer.. 26. 2015
Boning up on prognostic factors in advanced renal cell carcinoma.. 22. 2011
Endocrine resistance in breast cancer: what really matters?. 18. 2007
Matrix metalloproteinase inhibitors: how can we optimize their development?. 12. 2001
Hormone refractory metastatic prostate cancer.. 3. 1992
Quality of cancer clinical trials.. 1. 1990
Small cell lung cancer: a slightly less orphan disease after immunotherapy. 2021
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. 2020
Prognostic gene expression signature for high-grade serous ovarian cancer. 2020
Identifying patients with NTRK fusion cancer. 2019
TRK inhibitors in TRK fusion-positive cancers. 2019
Identifying patients with NTRK fusion cancer. 2019
TRK inhibitors in TRK fusion-positive cancers. 2019
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. 2018
New agents on the horizon in gastric cancer. 2017
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. 2017
Chemotherapy remains an essential element of personalized care for persons with lung cancers. 2016
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. 2016
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. 2016
Alopecia in patients treated with molecularly targeted anticancer therapies. 2015
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. 2015
Why has active immunotherapy not worked in lung cancer? 2015
Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. 2015
Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. 2014
Muscle dysfunction in cancer patients. 2014
Local approaches to hereditary breast cancer. 2013
Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. 2013
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. 2012
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. 2012
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. 2012
New drugs for ovarian cancer. 2011
Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). 2011
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. 2011
The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. 2011
Hereditary breast cancer: clinical features and risk reduction strategies. 2011
Advances in neuroendocrine lung tumors. 2010
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. 2008
New monoclonal antibodies for non-Hodgkin's lymphoma. 2008
Src as a potential therapeutic target in non-small-cell lung cancer. 2008
Treatment options in renal cell carcinoma: past, present and future. 2007
Epothilones in breast cancer: review of clinical experience. 2007
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. 2007
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. 2006
Muscle invasive and metastatic bladder cancer. 2006
Mantle cell lymphoma: an update on management. 2006
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005
Medical treatment of non-small-cell lung cancer. 2005
An overview of the status of imaging screening technology for breast cancer. 2004
Progress in the development and acquisition of anticancer agents from marine sources. 2003
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. 2003
Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? 2002
Pleura mesothelioma: combined modality treatments. 2002
The involved field is back: issues in delineating the radiation field in Hodgkin's disease. 2002
Treatment options in hormone resistant prostate cancer. 2002
Pharmacologic insights into the future of trastuzumab. 2001
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. 2000
Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects. 2000
Treatment of thymoma and thymic carcinoma. 2000
p53 and chemosensitivity. 1999
Current chemotherapeutic possibilities in pancreaticobiliary cancer. 1999
Mucin hypersecreting neoplasms. 1999
Pancreaticobiliary cancer: the future aspects of medical oncology. 1999
Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. 1997
The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. 1997
The treatment of advanced bladder cancer. 1995
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. 1995
Identification of genetic lesions associated with diffuse large-cell lymphoma. 1994
Single-agent use of Taxol (paclitaxel) in breast cancer. 1994
Combined-modality therapy in the treatment of local-regional esophageal cancer. 1992
Follicular lymphoma: a model of lymphoid tumor progression in man. 1991

VIVO Weill Cornell Medical College

Annals of oncology : official journal of the European Society for Medical Oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)